Dupixent is a prescription medication used to treat various conditions, including allergic rhinitis, asthma, and atopic ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

The injectable Dupixent, used for eczema, is almost three times as expensive as the weight loss GLP-1 Wegovy, with a list price of $47,916 a year compared to $16,188. But Wegovy is the drug that ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...